Racivir
![]() | |
Systematic (IUPAC) name | |
---|---|
4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one | |
Clinical data | |
Routes of administration | Investigational |
Identifiers | |
CAS Number | 137530-41-7 |
ATC code | none |
PubChem | CID 454858 |
ChemSpider | 400521 |
NIAID ChemDB | 005245 |
Chemical data | |
Formula | C8H10FN3O3S |
Molar mass | 247.25 g/mol |
| |
|
Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1] It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.

Emtricitabine, the enantiomer of racivir and a widely used NRTI
References
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.